-

10:44:30 AM

ARAV Stock News

ARAV - Aravive Inc

06/05/23 4:05 PM

Nasdaq : ARAV

conferenceslow float

Aravive To Participate in the Jefferies Global Healthcare Conference

Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial

RHEA-AI

neutral

05/25/23 5:00 PM

Nasdaq : ARAV

conferencesclinical triallow float

Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023

Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 2 trial of batiraxcept in clear

RHEA-AI

positive

05/16/23 7:05 AM

Nasdaq : ARAV

clinical triallow float

Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma

Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted

RHEA-AI

neutral

05/10/23 4:05 PM

Nasdaq : ARAV

earningslow float

Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates

On Track for PROC Pivotal Phase 3 Trial Readout Mid-2023 Promising ccRCC Phase 1b/2 Results to Date; Update to be Presented at ASCO 2023 Strengthened Management Team with Appointment of Carolina Petrini as Chief Commercial Officer Company hosting Key Opinion Leader (KOL) webinar featuring

RHEA-AI

neutral

05/08/23 7:05 AM

Nasdaq : ARAV

conferenceslow float

Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept

Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced it will host a virtual Key

RHEA-AI

very positive

04/26/23 5:00 PM

Nasdaq : ARAV

low float

Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting

Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of a poster featuring batiraxcept data in clear cell renal cell carcinoma

RHEA-AI

neutral

04/11/23 7:05 AM

Nasdaq : ARAV

managementlow float

Aravive Appoints Carolina Petrini as Chief Commercial Officer

Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Carolina Petrini as the Company’s new Chief Commercial Officer effective

RHEA-AI

very positive

03/15/23 7:00 AM

Nasdaq : ARAV

earningslow float

Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic

RHEA-AI

very positive

02/28/23 4:05 PM

Nasdaq : ARAV

low float

Aravive Announces FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer

Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to

RHEA-AI

very positive

02/13/23 5:00 PM

Nasdaq : ARAV

conferencesclinical triallow float

Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium

Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 1b/2 trial of batiraxcept in

RHEA-AI

very positive

1 2 3 4 5 6 7 Next

ARAV Data

IndustryPharmaceutical Preparation Manufacturing
Websitearavive.com
CeoGail McIntyre
Security nameAravive Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees23
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressRiver Oaks Tower
Address23730 Kirby Drive, Suite 1200
StateTexas
CityHouston
Zip77098
CountryUS
Phone19363551910

About Aravive Inc

Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. Aravive's lead product candidate, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth. Aravive successfully completed a Phase 1b trial of AVB-500 in platinum resistant ovarian cancer and has initiated a registrational Phase 3 trial of AVB-500 at a dose of 15 mg/kg. While the Phase 1b trial of AVB-500 in platinum resistant ovarian cancer was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mg/kg cohort experienced clinical benefit, with 1 complete response, 2 partial responses, and 2 stable disease. The Company is dosing patients in its Phase 1b/2 trial in clear cell renal cell carcinoma.